Ensysce Biosciences, Inc. cash flow statement
In fiscal 2025, Ensysce Biosciences, Inc.'s operations generated −$7.8m of cash; it spent $123,643 on capital projects, leaving free cash flow of −$7.9m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −1 | −8 | −18 | −11 | −8 | −8 | −9 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Capital spending | — | — | — | — | — | 0 | — |
| Free cash flow | — | — | — | — | — | −8 | — |
| Free cash flow after stock pay | — | — | — | — | — | −8 | — |
| Share buybacks | 185 | — | — | — | — | — | — |
| Shares issued | −185 | 7 | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,020 | −764 | −1,707 | −2,707 | −1,866 | −1,526 | −3,501 | −1,962 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 7 |
| Stock-based pay | 21 | 30 | 16 | 91 | 46 | 24 | 9 | 2 |
| Capital spending | — | — | — | — | — | 0 | — | 0 |
| Free cash flow | — | — | — | — | — | −1,526 | — | −1,962 |
| Free cash flow after stock pay | — | — | — | — | — | −1,550 | — | −1,964 |
| Shares issued | — | — | — | — | −400 | — | — | — |
Compare with peers
- Ocugen, Inc. cash flow
- Entrada Therapeutics, Inc. cash flow
- Curis Inc cash flow
- Bolt Biotherapeutics, Inc. cash flow
- Camp4 Therapeutics Corp cash flow
Head to head: ENSC vs OCGNENSC vs TRDACRIS vs ENSCCAMP vs ENSC
More: Biotechnology stocks compared, Health Care sector, rankings of US companies